Table 2.
Clinical and laboratory parameters in patients undergoing MMF treatment in the included studies.
| Study | At MMF onset | At the follow-up period of 6 months | Mean does of MMF per day (g/day) | P-vaule |
|---|---|---|---|---|
| Serum creatinine | ||||
| Joy et al. (14) | 2.3 ± 2.2 (mg/dL)* | 1.8 ± 1.2 (mg/dL)* | 2.0–3.0 | 0.4679 |
| Stassen et al. (15) | 106 (73–542) μmol/l # | CR: 110 (73–500) μmol/l NR and PR: 99 (88–542) μmol/l# | 2.0 | NA |
| Hu et al. (17) | 3.55 ± 1.1 (mg/dL)* | NA | 1.5–2.0 | NA |
| Han et al. (18) | 318.7 ± 283.4 mol/l* | 114.9 μmol/l (mean sCr level) | 1.0 | NA |
| Mean ANCA titres | ||||
| Joy et al. (14) | 57 ± 29.2 μ/ml* | 43.3 ± 35.0 μ/ml* | 2.0–3.0 | 0.3736 |
| Silva et al. (31) | 54 (16–113) EU/ml# | 5 (4–10) EU/ml# | 1.5–2.0 | <0.01 |
| Han et al. (18) | 97.6 ± 88.7 μ/ml * | 22.4 μ/ml (mean anti-MPO antibody level) | 1.0 | NA |
| BVAS | ||||
| Stassen et al. (15) | 14 (5–29)# | CR: 13 (5–29); NR and PR: 15 (6–27)# | 2.0 | NA |
| Hu et al. (17) | 15.6 ± 3.3* | 0.2 ± 0.89* | 1.5–2.0 | NA |
| Han et al. (18) | 17.8 ± 4.2* | NA | 1.0 | NA |
| Jones et al. (10) | 19 (13–25)# | NA | 2.0–3.0 | NA |
| Tuin et al. (19) | 15 (13–19)# | NA | 2.0 | NA |
| CRP | ||||
| Stassen et al. (15) | 39 (1–361) mg/l# | CR: 39 (1–311) mg/l; NR and PR: 35 (6–361) mg/l# | 2.0 | NA |
| Silva et al. (31) | 0.5 (0.3–35.3) mg/dl# | NA | 1.5–2.0 | NA |
| Han et al. (18) | 35.7 ± 50.2 mmol/l* | NA | 1.0 | NA |
| Jones et al. (10) | 22 (7.5–52) mg/L# | NA | 2.0–3.0 | NA |
| Tuin et al. (19) | 33 (10–57) mg/L# | NA | 2.0 | NA |
| ESR | ||||
| Silva et al. (31) | 38 (24–73) mm/h# | NA | 1.5–2.0 | NA |
| Han et al. (18) | 76.1 ± 43.0 mm/h* | NA | 1.0 | NA |
| Jones et al. (10) | 54 (31–98) mm/h# | NA | 2.0–3.0 | NA |
| eGFR | ||||
| Silva et al. (31) | 46 (34–63) ml/min# | 47 (33–72) ml/min# | 1.5–2.0 | NA |
| Han et al. (18) | 35.5 ± 29.2 ml/min/1.73 m2* | 21.64 ml/min/1.73 m2 (mean eGFR level) | 1.0 | NA |
| Jones et al. (10) | 51 (29–92) ml/min/1.73 m2# | NA | 2.0–3.0 | NA |
| Proteinuria | ||||
| Hu et al. (17) | 3.05 ± 2.85 (g/24 h)* | NA | 1.5–2.0 | NA |
| Silva et al. (31) | 889 (400–2,208) mg/24 h# | 384 (151–1,071) mg/24 h# | 1.5–2.0 | <0.01 |
| Han et al. (18) | 2.21 ± 1.68 (g/24 h) * | 1.256 g/24 h (mean proteinuria level) | 1.0 | NA |
#
Median (range);
*
Mean ± standard variance; BVAS, Birmingham Vasculitis Activity Score; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; eGFR, estimated glomerular filtration rate; NA, not available.